行情

HCM

HCM

HUTCHMED (China) Limited
NASDAQ

实时行情|Nasdaq Last Sale

29.20
+0.84
+2.96%
盘后: 29.20 0 0.00% 16:00 06/18 EDT
开盘
28.31
昨收
28.36
最高
29.37
最低
27.88
成交量
107.64万
成交额
--
52周最高
37.00
52周最低
23.01
市值
43.48亿
市盈率(TTM)
-324.0844
分时
5日
1月
3月
1年
5年
一周新股 | 奈雪的茶孖展火热,时代天使上市引爆IPO市场
新浪财经 · 13小时前
和黄医药:超10亿元处方药收入 填不满创新研发“无底洞”?
智通财经APP · 20小时前
和黄医药(00013.HK):苏泰达在內地註册审批已经完成并获得认证
金融界 · 23小时前
Hutchmed 申请超过 6 亿美元的香港首次公开募股
Benzinga · 1天前
Hutchmed(中国)治疗胰腺肿瘤在中国获批
marketwatch.com · 1天前
和黄医药索凡替尼就治疗晚期胰腺NET的中国药监局药品注册审批已完成
智通财经 · 1天前
和黄医药(00013.HK):索凡替尼就治疗晚期胰腺NET药品注册审批完成并正待获得认证
格隆汇APP · 1天前
全球三地布局!和黄医药将在港IPO 目前尚未盈利
中国证券报 · 1天前
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解HCM最新的财务预测,通过HCM每股收益,每股净资产,每股现金流等数据分析HUTCHMED (China) Limited近期的经营情况,然后做出明智的投资选择。
分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测HCM价格均价为41.15,最高价位45.00,最低价为36.20。
EPS
机构持股
总机构数: 167
机构持股: 5,394.82万
持股比例: 36.23%
总股本: 1.49亿
类型机构数股数
增持
54
376.41万
建仓
14
33.08万
减持
41
177.32万
平仓
8
176.21万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
-1.19%
制药与医学研究
-0.98%
高管信息
Chairman/Director
Simon To
Chief Executive Officer/Executive Director/IR Contact Officer
Christian Hogg
Chief Financial Officer/Executive Director
Chig Fung Cheng
Executive Director
Weiguo Su
Secretary/Non-Executive Director
Edith Shih
Non-Executive Director
Dan Eldar
Non-Executive Independent Director
Paul Carter
Non-Executive Independent Director
Karen Ferrante
Non-Executive Independent Director
Graeme Jack
Non-Executive Independent Director
Shu Kam Mok
暂无数据
HCM 简况
HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.

微牛提供HUTCHMED (China) Ltd(NASDAQ-HCM)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的HCM股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易HCM股票基本功能。